Znn3bq.jpeg
ÉÇÍ·´óѧº£Ñó¿ÆÑ§½ÓÊܵ÷¼Á
²é¿´: 628  |  »Ø¸´: 9

linglingchen

Ìú³æ (СÓÐÃûÆø)


[½»Á÷] Science£º×¢ÉäÇ¿Á¦¿¹ÌåÒÖÖÆÑªÒºÖÐHIV²¡¶¾

12ÔÂ23ÈÕ£¬À´×ÔÃÀ¹úNIHµÄ¿ÆÑ§¼ÒÃÇÔÚ¹ú¼ÊѧÊõÆÚ¿¯ÉÏ·¢±íÁËÒ»Ïî×îÐÂÑо¿½øÕ¹£¬ËûÃDZ¨¸æ³Æ×¢ÉäÒ»ÖÖ½Ð×öVRC01µÄǿЧ¿¹Ìå¾ÍÄܹ»ÒÖÖÆÎ´½ÓÊÜ¿¹Äæ×ªÂ¼²¡¶¾ÖÎÁƵÄHIVЯ´øÕßѪҺÖеÄHIV²¡¶¾Ë®Æ½¡£Ñо¿ÈËÔ±»¹·¢ÏÖͨ¹ý¾²Âö×¢Éä»òƤÏÂ×¢É䷽ʽ½«VRC01¿¹Ìå×¢È벡¶¾Ð¯´øÕßÌåÄÚ¾ßÓзdz£ºÃµÄ°²È«ÐÔºÍÄÍÊÜÐÔ£¬²¢ÇÒ×¢ÈëµÄ¿¹ÌåÄܹ»ÔÚ²¡ÈËѪҺÖб£³Ö½Ï³¤Ê±¼ä¡£
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
http://stm.sciencemag.org/content/7/319/319ra206

Passive aggression for HIV

Antibodies that neutralize HIV could add to the therapeutic arsenal to prevent and treat disease. Lynch et al. have now tested one such antibody¡ªVRC01¡ªin HIV-infected individuals. Although little difference was observed in viral reservoir in individuals on antiretroviral therapy, plasma viremia was reduced in untreated subjects with a single infusion of VRC01, preferentially suppressing neutralization-sensitive strains. Passive immunization with neutralizing antibodies could therefore aid in viral suppression in HIV-infected individuals.
Abstract

Passive immunization with HIV-1¨Cneutralizing monoclonal antibodies (mAbs) is being considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs could be used to suppress active virus replication, maintain suppression induced by antiretroviral therapy (ART), and/or decrease the size of the persistent virus reservoir. We assessed the impact of VRC01, a potent human mAb targeting the HIV-1 CD4 binding site, on ART-treated and untreated HIV-1¨Cinfected subjects. Among six ART-treated individuals with undetectable plasma viremia, two infusions of VRC01 did not reduce the peripheral blood cell¨Cassociated virus reservoir measured 4 weeks after the second infusion. In contrast, six of eight ART-untreated, viremic subjects infused with a single dose of VRC01 experienced a 1.1 to 1.8 log10 reduction in plasma viremia. The two subjects with minimal responses to VRC01 were found to have predominantly VRC01-resistant virus before treatment. Notably, two subjects with plasma virus load <1000 copies/ml demonstrated virus suppression to undetectable levels for over 20 days until VRC01 levels declined. Among the remaining four subjects with baseline virus loads between 3000 and 30,000 copies, viremia was only partially suppressed by mAb infusion, and we observed strong selection pressure for the outgrowth of less neutralization-sensitive viruses. In summary, a single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains. These data demonstrate the virological effect of this neutralizing antibody and highlight the need for combination strategies to maintain virus suppression.
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

´ósusu

Ìú³æ (СÓÐÃûÆø)


°²È«ÐÔºÍÄÍÊÜÐÔ£¬ÒѾ­½øÈëÁÙ´²ºóÆÚÁËô£¿
9Â¥2016-01-10 22:44:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ttshi2013

гæ (³õÈëÎÄ̳)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ScienceÉϵÄÎÄÕ£¬Ç°ÑØÐÔ»¹ÊDz»´íµÄ¡£
10Â¥2016-01-15 11:20:45
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
jiantu2Â¥
2015-12-29 10:31   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
liangbk3Â¥
2015-12-29 11:05   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
bit_14Â¥
2015-12-29 11:30   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
tan9145Â¥
2015-12-29 12:10   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
tan9146Â¥
2015-12-29 12:13   »Ø¸´  
psylhh7Â¥
2015-12-29 12:14   »Ø¸´  
linglingchen(½ð±Ò+1): лл²ÎÓë
2015-12-30 09:12   »Ø¸´  
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ linglingchen µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 279ѧ˶ʳƷרҵÇóµ÷¼ÁԺУ 20+6 ¹Â¶ÀµÄÀǰ®³ÔÑò 2026-04-12 26/1300 2026-04-14 09:04 by zs92450
[¿¼ÑÐ] 305Çóµ÷¼Á +8 Â꿨°Í¿¨boom 2026-04-11 8/400 2026-04-14 09:04 by pengliang8036
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£©½ÓÊÜ¿çרҵ +9 ÏàÐűػá¹ââÍòÕ 2026-04-13 9/450 2026-04-14 09:00 by pengliang8036
[¿¼ÑÐ] Çóµ÷¼ÁѧУ +6 ²»»á³ÔÈâ 2026-04-13 6/300 2026-04-14 08:36 by ľľmumu¡«
[¿¼ÑÐ] È˹¤ÖÇÄÜ320µ÷¼Á08¹¤À໹Óлú»áÂð +17 Õñ¡ªTZ 2026-04-10 18/900 2026-04-14 08:15 by Equinoxhua
[¿¼ÑÐ] 271Çóµ÷¼Á +34 2261744733 2026-04-11 40/2000 2026-04-13 23:15 by pies112
[¿¼ÑÐ] 279Çóµ÷¼Á +11 ÕÅ·¬ÇѲ»³´µ° 2026-04-11 11/550 2026-04-13 22:25 by zhq0425
[¿¼ÑÐ] Ò»Ö¾Ô¸»ª¹¤085600 331·Ö +7 ÌìÏÂww 2026-04-09 7/350 2026-04-13 09:01 by lhj2009
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ289 085602 +33 yangæÃ 2026-04-10 34/1700 2026-04-12 08:11 by Art1977
[¿¼ÑÐ] 331Çóµ÷¼Á +5 Íõ¹ú˧ 2026-04-11 5/250 2026-04-11 22:56 by Ϫ½§Á÷Ë®
[¿¼ÑÐ] 296Çóµ÷¼Á +8 Íô£¡£¿£¡ 2026-04-09 8/400 2026-04-11 21:02 by ÄæË®³Ë·ç
[¿¼ÑÐ] µ÷¼Á +5 ÎĵÀÐÇ̨ 2026-04-11 5/250 2026-04-11 15:01 by ¿­¿­Òª±ä˧
[¿¼ÑÐ] 297Çóµ÷¼Á +9 Kwgyz 2026-04-09 9/450 2026-04-11 10:09 by zhq0425
[¿¼ÑÐ] Ò»Ö¾Ô¸¾©Çø985£¬085401µç×ÓÐÅÏ¢£¬±¾¿Æµç×ÓÐÅÏ¢ +3 Ñô¹â¿ªÀʵÄÄк¢ 2026-04-10 3/150 2026-04-10 16:29 by sophia_93
[¿¼ÑÐ] 085800 ÄÜÔ´¶¯Á¦Çóµ÷¼Á +6 °¢biu°¡°¡°¡°¡°¡ 2026-04-10 6/300 2026-04-10 15:03 by hemengdong
[¿¼ÑÐ] 085404£¬285·ÖÇóµ÷¼Á +12 Þ±Þ±¿¼ÑÐ 2026-04-07 14/700 2026-04-09 23:10 by parmtree
[¿¼ÑÐ] ¿¼Ñе÷¼Á-²ÄÁÏÀà-284 +28 Ïë»»ÊÖ»ú²»Ïë½âÊ 2026-04-08 28/1400 2026-04-09 20:08 by µ¹Êý321?
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á +21 ²»ÖªÃûµÄСئ 2026-04-08 21/1050 2026-04-09 18:55 by l_paradox
[¿¼ÑÐ] 367Çóµ÷¼Á +10 hffQAQ 2026-04-09 10/500 2026-04-09 18:06 by lijunpoly
[¿¼ÑÐ] ÉúÎïѧѧ˶£¬³õÊÔ351·Ö£¬Çóµ÷¼Á +4 ¡­¡«¡¢Íõ¡­¡« 2026-04-08 5/250 2026-04-08 21:49 by limeifeng
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û